E7130

Harvard Breakthrough Anti-Cancer Agent E7130 Nearing Clinicals

Jun 19, 2019 | Anti-Cancer Agent, E7130, Eisai, Halichondrin, Harvard

Harvard University chemists have achieved a “landmark in drug discovery” with the synthesis of halichondrin, known to be a potent anti-cancer agent in preclinical mouse studies. Naturally found in sea sponges in tiny quantities, the halichondrin class of molecule is...

TRIALSITE NEWS IS THE ONLY DIGITAL MEDIA DEDICATED 100% TO TRANSPARENT AND OPEN COVERAGE OF CLINICAL RESEARCH TRIAL SITES AROUND THE GLOBE. BASED IN THE SILICON SLOPES IN DOWNTOWN SALT LAKE CITY, UTAH, WE ARE FOUNDED BY A TEAM OF EXPERTS IN THE CLINICAL TRIALS INDUSTRY AND DEDICATED TO TRANSPARENCY, QUALITY AND CLINICAL TRIAL INNOVATION.

159 WEST BROADWAY SUITE 200
SALT LAKE CITY, UT 84101

Harvard Breakthrough Anti-Cancer Agent E7130 Nearing Clinicals

Pin It on Pinterest